000087540 001__ 87540
000087540 005__ 20200716101434.0
000087540 0247_ $$2doi$$a10.1016/j.atherosclerosis.2019.01.024
000087540 0248_ $$2sideral$$a110894
000087540 037__ $$aART-2019-110894
000087540 041__ $$aeng
000087540 100__ $$aBea, A.M.
000087540 245__ $$aLipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene
000087540 260__ $$c2019
000087540 5060_ $$aAccess copy available to the general public$$fUnrestricted
000087540 5203_ $$aBackground and aims: The aim of this work was to compared the effect of lipid lowering drugs among familial hypercholesterolemia (FH) subjects with a functional mutation in LDLR (LDLR FH) and FH with the p.(Leu167del) mutation in APOE.
Methods: We retrospectively selected all adults with the p.(Leu167del) mutation on lipid-lowering treatment (n = 22) attending the Lipid Unit at the Hospital Miguel Servet. Age and sex matched LDLR FH from the same Unit were randomly selected as a control group (n = 44).
Results: The mean percentage reduction in LDLc was significantly higher in the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on high intensity statins. Similar differences between groups were observed in non-HDLc -49.4% and -36.4%, respectively (p = 0.030).
Conclusions: Subjects with p.(Leu167del) mutation have a higher lipid-lowering response to statins with or without ezetimibe than LDLR FH. This supports the use of genetics for a more efficient management of FH.
000087540 536__ $$9info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europe$$9info:eu-repo/grantAgreement/ES/MINECO/PI13-02507$$9info:eu-repo/grantAgreement/ES/MINECO/PI15-01983
000087540 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000087540 590__ $$a3.919$$b2019
000087540 592__ $$a1.515$$b2019
000087540 591__ $$aPERIPHERAL VASCULAR DISEASE$$b16 / 65 = 0.246$$c2019$$dQ1$$eT1
000087540 593__ $$aCardiology and Cardiovascular Medicine$$c2019$$dQ1
000087540 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b42 / 138 = 0.304$$c2019$$dQ2$$eT1
000087540 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000087540 700__ $$aLamiquiz-Moneo, I.
000087540 700__ $$aMarco-Benedí, V.
000087540 700__ $$0(orcid)0000-0001-6650-8294$$aMateo-Gallego, R.$$uUniversidad de Zaragoza
000087540 700__ $$aPérez-Calahorra, S.
000087540 700__ $$0(orcid)0000-0001-9142-0737$$aJarauta, E.$$uUniversidad de Zaragoza
000087540 700__ $$aMartín, C.
000087540 700__ $$aCenarro, A.
000087540 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000087540 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000087540 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000087540 773__ $$g282 (2019), 143-147$$pAtherosclerosis$$tAtherosclerosis$$x0021-9150
000087540 8564_ $$s156287$$uhttps://zaguan.unizar.es/record/87540/files/texto_completo.pdf$$yPostprint
000087540 8564_ $$s190982$$uhttps://zaguan.unizar.es/record/87540/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000087540 909CO $$ooai:zaguan.unizar.es:87540$$particulos$$pdriver
000087540 951__ $$a2020-07-16-08:53:13
000087540 980__ $$aARTICLE